{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:59:24Z","timestamp":1777517964024,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.iac.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T16:42:39Z","timestamp":1531586559000},"page":"429-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Gastrointestinal Involvement in Mast Cell Activation Disorders"],"prefix":"10.1016","volume":"38","author":[{"given":"Fred H.","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib1","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.iac.2018.04.008_bib2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.iac.2014.01.010","article-title":"Pathology of extramedullary mastocytosis","volume":"34","author":"Doyle","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.iac.2018.04.008_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.iac.2013.09.001","article-title":"Mastocytosis","volume":"34","author":"Carter","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"10.1016\/j.iac.2018.04.008_bib5","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ibd.21218","article-title":"Gastrointestinal involvement and manifestations in systemic mastocytosis","volume":"16","author":"Sokol","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.iac.2018.04.008_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0889-8588(05)70298-7","article-title":"Gastrointestinal abnormalities and involvement in systemic mastocytosis","volume":"14","author":"Jensen","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"10.1016\/j.iac.2018.04.008_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0016-5085(88)80012-X","article-title":"Gastrointestinal dysfunction in systemic mastocytosis: a prospective study","volume":"95","author":"Cherner","year":"1988","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.iac.2018.04.008_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.04.008_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7326\/0003-4819-59-2-194","article-title":"The mastocytosis syndrome: clinical and biological studies","volume":"59","author":"Demis","year":"1963","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.iac.2018.04.008_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.7326\/0003-4819-59-6-887","article-title":"Systemic mast cell disease","volume":"59","author":"Mutter","year":"1963","journal-title":"Ann Intern Med"},{"issue":"3 Suppl","key":"10.1016\/j.iac.2018.04.008_bib11","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1111\/1523-1747.ep12468899","article-title":"Systemic mastocytosis: retrospective review of a decade\u2019s clinical experience at the Brigham and Women\u2019s Hospital","volume":"96","author":"Horan","year":"1991","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease. Analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-008-0166-4","article-title":"Advanced mast cell disease: an Italian Hematological Multicenter experience","volume":"88","author":"Pagano","year":"2008","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/1097-0142(19820301)49:5<927::AID-CNCR2820490517>3.0.CO;2-B","article-title":"Systemic mast cell disease: a clinical and hematopathologic study of 26 cases","volume":"49","author":"Webb","year":"1982","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.iac.2018.04.008_bib15","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/0002-9343(86)90622-4","article-title":"Hepatic involvement in systemic mast cell disease","volume":"80","author":"Yam","year":"1986","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.iac.2018.04.008_bib17","doi-asserted-by":"crossref","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.iac.2018.04.008_bib18","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1097\/01.pas.0000213310.51553.d7","article-title":"Systemic mastocytosis mimicking inflammatory bowel disease: a case report and discussion of gastrointestinal pathology in systemic mastocytosis","volume":"30","author":"Bedeir","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0016-5107(96)70019-6","article-title":"Endoscopic findings in systemic mastocytosis","volume":"44","author":"Scolapio","year":"1996","journal-title":"Gastrointest Endosc"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0091-6749(94)90371-9","article-title":"Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation","volume":"93","author":"Awad","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0016-5085(82)80263-1","article-title":"A\u00a0new syndrome of symptomatic cutaneous mastocytoma producing vasoactive intestinal polypeptide","volume":"82","author":"Wesley","year":"1982","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-90-5-769","article-title":"Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis","volume":"90","author":"Hirschowitz","year":"1979","journal-title":"Ann Intern Med"},{"issue":"4 PART 1","key":"10.1016\/j.iac.2018.04.008_bib23","first-page":"1163","article-title":"Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases","volume":"22","author":"Mican","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.iac.2018.04.008_bib24","doi-asserted-by":"crossref","first-page":"728172","DOI":"10.1155\/2012\/728172","article-title":"Systemic mastocytosis: a rare case of increased liver stiffness","volume":"2012","author":"Adolf","year":"2012","journal-title":"Case Reports Hepatol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.008_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/flgastro-2011-100013","article-title":"Systemic mastocytosis: a gastroenterological perspective","volume":"3","author":"Philpott","year":"2012","journal-title":"Frontline Gastroenterol"},{"issue":"12","key":"10.1016\/j.iac.2018.04.008_bib26","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/modpathol.2008.158","article-title":"Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases","volume":"21","author":"Kirsch","year":"2008","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.iac.2018.04.008_bib27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/PAS.0b013e318078ce7a","article-title":"Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis","volume":"31","author":"Hahn","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A\u00a0clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.iac.2018.04.008_bib29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1309\/2880LF7Q6XK3HA3Q","article-title":"Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis?","volume":"122","author":"Siegert","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.iac.2018.04.008_bib30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0002-9343(80)90476-3","article-title":"The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis","volume":"69","author":"Achord","year":"1980","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000017978","article-title":"Cutaneous mastocytosis in adults. evaluation of 14 patients with respect to systemic disease manifestations","volume":"197","author":"Tebbe","year":"1998","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2133.1988.tb03467.x","article-title":"Intestinal mucosal mast cells: enumeration in urticaria pigmentosa and systemic mastocytosis","volume":"119","author":"Ferguson","year":"1988","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.iac.2018.04.008_bib33","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000096442","article-title":"Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome","volume":"142","author":"Sonneck","year":"2007","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.iac.2018.04.008_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anai.2014.05.001","article-title":"Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome","volume":"113","author":"Jagdis","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11\u201312","key":"10.1016\/j.iac.2018.04.008_bib36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00251-010-0474-8","article-title":"Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects","volume":"62","author":"Molderings","year":"2010","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.iac.2018.04.008_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2014.11.035","article-title":"Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels","volume":"136","author":"Zanotti","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.008_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.008_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib42","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.008_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of mast cell activation syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.iac.2018.04.008_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib45","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"\u00c1lvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2018.04.008_bib46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.5858\/2006-130-362-MEIMMC","article-title":"Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea","volume":"130","author":"Jakate","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.iac.2018.04.008_bib47","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.iac.2018.04.008_bib48","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gut.2010.213108","article-title":"The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome","volume":"59","author":"Klooker","year":"2010","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.iac.2018.04.008_bib49","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/jid.2009.134","article-title":"Desloratadine inhibits human skin mast cell activation and histamine release","volume":"129","author":"Weller","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib50","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/0091-6749(89)90097-3","article-title":"A\u00a0double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis","volume":"83","author":"Kettelhut","year":"1989","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.iac.2018.04.008_bib51","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/all.12159","article-title":"Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Siebenhaar","year":"2013","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.iac.2018.04.008_bib52","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/all.12672","article-title":"H\u00a01 -antihistamines for primary mast cell activation syndromes: a systematic review","volume":"70","author":"Nurmatov","year":"2015","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.iac.2018.04.008_bib53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0091-6749(93)90076-R","article-title":"Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis","volume":"92","author":"Friedman","year":"1993","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib54","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2222.1991.tb00828.x","article-title":"Effects of tixocortol pivalate on gastrointestinal disease in systemic mastocytosis: a preliminary study","volume":"21","author":"Friedman","year":"1991","journal-title":"Clin Exp Allergy"},{"issue":"3\u20134","key":"10.1016\/j.iac.2018.04.008_bib56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"5","key":"10.1016\/j.iac.2018.04.008_bib57","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.anai.2015.08.016","article-title":"Response to celecoxib in a patient with indolent systemic mastocytosis presenting with intractable diarrhea","volume":"115","author":"Moreno-Borque","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.iac.2018.04.008_bib58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","article-title":"Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis","volume":"29","author":"Turner","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib59","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2018.04.008_bib60","doi-asserted-by":"crossref","first-page":"903541","DOI":"10.1155\/2015\/903541","article-title":"Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab","volume":"2015","author":"Lieberoth","year":"2015","journal-title":"Case Rep Med"},{"issue":"6","key":"10.1016\/j.iac.2018.04.008_bib61","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856118300341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T16:26:58Z","timestamp":1661617618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856118300341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0889856118300341"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.008","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal Involvement in Mast Cell Activation Disorders","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}